Archive Category: Green Zone Fortunes Updates

This week, I discuss the stock that Adam O’Dell and I chose for the May issue of Green Zone Fortunes: Supernus Pharmaceuticals (Nasdaq: SUPN). With its new, disruptive ADHD prescription, Qelbree, we’re convinced that Supernus is a game changer for adults and children alike.

When I learned about the latest medical innovation of the company I’m sharing with you today, I researched the stock and saw how it stacks up in our Green Zone Ratings system. It was clear that I needed to share it with you, my Green Zone Fortunes readers. I told my co-editor Charles Sizemore and my team that I had to write this issue. I was that pumped to tell you about this stock.

Today, we’re talking all about our Imperium DNA powerhouse, Twist Bioscience (Nasdaq: TWST). First, congratulations to the folks who got into from the beginning. I recommended this company in the May 2020 issue of Green Zone Fortunes. You’ve already had the chance to lock in partial profits of up to 100% on part of your position.

I’ve been saying that our “Imperium” stock, Twist Bioscience Corp. (Nasdaq: TWST), has the potential to be a $1,000 stock, and that hasn’t changed.

This week, I discuss how the Federal Reserve has given us trillions of reasons to focus on gold — and I do a deep dive on our gold miner Agnico Eagle (NYSE: AEM) after its latest earnings announcement. I also explain why chief investment strategist Adam O’Dell and I are still bullish on our competitive gaming play, Turtle Beach Corp. (Nasdaq: HEAR) — including the latest news about an activist investor.